Why BENLYSTA?

Dr. Alvin Wells, Rheumatologist

Paid consultant to GSK at the time of filming.

video transcript

ON-SCREEN TEXT: “Why BENLYSTA?”
Stay tuned for Important Product Information

ON-SCREEN TEXT: Dr. Alvin Wells, Rheumatologist
Paid consultant to GSK at the time of filming.

DR WELLS: Many of my rheumatology colleagues ask me all the time, “Why BENLYSTA?” I always tell them to take a step back and think about where we are in treating any patient in medicine now. We should be trying to use, to the best of our ability, evidence-based medicine.

ON-SCREEN TEXT: “Evidence-based medicine”

DR WELLS: And what does “evidence-based medicine” look like? It means that we have taken clinical trial data from randomized, placebo-controlled trials, data from peer-reviewed journals, and data that has been approved by the FDA to treat our patients. And fast forward, that’s where we are in using BENLYSTA in our patients with lupus.

ON-SCREEN TEXT: “Approved by the FDA”

DR WELLS: I also remind them and say when BENLYSTA was approved, we hadn’t had a drug for a number of years in treating patients with lupus. Before this, we had had drugs we kind of had borrowed and stolen from other specialties like oncology, drugs that go back into the 50s and into the 60s.

DR WELLS: So, when BENLYSTA came out, and remember this drug was designed to treat lupus, and targeting the underlying disease activity, the mechanism of action really kind of drives home that and that improvement that we see in our patients.

ON-SCREEN TEXT: BENLYSTA targets underlying disease activity

DR WELLS: So overall we talk about BENLYSTA, a drug that is designed specifically for disease activity in patients with lupus, a drug that has been FDA approved, that has a wealth of data around it, BENLYSTA has been a significant component of my armamentarium in treating patients with lupus disease activity.

ON-SCREEN TEXT: “BENLYSTA has been a significant component of my armamentarium”

ON-SCREEN TEXT: BENLYSTAHCP.com

DR. WELLS: Thank you for watching. Visit the BENLYSTA website for more information.

ON-SCREEN BUTTON: Visit the website

VOICEOVER:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active central nervous system lupus. Reported: serious & sometimes fatal infections; progressive multifocal leukoencephalopathy; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

ON-SCREEN TEXT:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5+ with active SLE or active lupus nephritis. Not for use in severe active CNS lupus. Reported: serious & sometimes fatal infections; PML; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

ON-SCREEN TEXT:
BENLYSTA
(belimumab)
Intravenous Use 120 mg/vial
Subcutaneous Use 200 mg/mL

GSK Logo

Trademarks are owned by or licensed to the GSK group of companies.
©2022 GSK or licensor. BELVID220045 August 2022 Produced in USA.

You may also like

BENLYSTA patient story

Dr. Alvin Wells, Rheumatologist

Why BENLYSTA?

Dr. Don Thomas, Rheumatologist

Paid consultants to GSK at the time of filming.

Icon: Computer

Join us for a live webinar

Learn more